26Jul 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

The study evaluated intensive chemotherapy with or without the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in patients with newly diagnosed NPM1-mutated acute myeloid leukaemia. Although the primary endpoints of short-term event-free survival and overall survival were not met, gemtuzumab ozogamicin showed anti-leukaemic efficacy with a significantly lower cumulative incidence of relapse rate. This suggests that adding gemtuzumab ozogamicin could reduce the need for salvage therapy in these patients.

  • #oncology

Like

Save

Share